Funding Opportunities Annoucements in HIV-Associated Malignancies

Office of HIV and AIDS Malignancy

National Cancer Institute

Cancer in Africa: A Significant Problem

Adapted from Sylla and Wild, Int J Cancer. 2012 Jan 15;130(2):245-50. 

Th

ou

sa

nd

RFA-CA-13-010Sub-Saharan African Collaborative HIV and Cancer

Consortia (U54)

Solicit research projects that are conducted jointly between U.S. investigators and investigators in a partnering sub-Saharan African country.

Projects must address high-priority research questions in HIV-associated cancers of the partnering African country.

Activities should be conducted in the partnering African country and should demonstrate an equal and shared partnership.

Applicants must identify a distinct research theme and focus activities around that theme.

Research projects should either address a variety of topics for a single category of cancer or one topic for a related group of cancers.

No clinical trials will be allowed but clinical research will be allowed.

RFA-CA-13-010Sub-Saharan African Collaborative HIV and Cancer

Consortia (U54)

The RFA was developed in collaboration with the Fogarty International Center (FIC).

RFA will be open to all qualified applicants, not just D43 Research Training recipients.

The U54 grant mechanism will be used. Supports a full range of research (basic, translational and clinical) Allows multiple projects in a single application Allows for scientific and programmatic input from OHAM staff

Each application must propose 2-4 research projects and necessary cores (Mentoring/Career Development & Administrative/Coordinating Cores are mandatory).

Applicants can request up to $750,000 TOTAL cost per year for 5 years.

NCI and FIC expect to fund 6-7 awards (~$4.4 million)

RFA-CA-13-010 Important Dates

Letter of Intent Due Date December 17, 2013

Application Due Date January 17, 2014

Scientific Merit Review (NCI DEA) March-April, 2014

Advisory Council Review May 2014 (NCAB meets June 22-24, 2014)

Earliest Start Date August 2014

U.S.-South Africa Program for Collaborative Biomedical Research

NOT-AI-13-066 (Notice of Intent to Publish a Request for Applications for the U.S.-South Africa Program for Collaborative Biomedical Research)

To enhance cooperative biomedical research between U.S. and South Africa The NIH and the MRC have allocated funds to support joint activities under

this program. FOCUS of the joint program:

HIV/AIDS biomedical and behavioral research Tuberculosis HIV-related malignancies

This RFA will support basic, translational, clinical, preventive or epidemiological research projects.

Clinical trials of drugs, biologics or diagnostics will not be allowed. Collaborating U.S. and South African Investigators will submit one application.

Each application will have at least one PI from each country Separate research budgets for each component Applications will be reviewed by NIH; MRC will not conduct a separate

review

Administrative Supplements for HIV/AIDS Implementation Science in PEPFAR Settings

NOT-AI-13-061 (Notice of Intent to Publish an Announcement for Availability of Funds for Administrative Supplements for HIV/AIDS Implementation Science in PEPFAR Settings)

By November/December 2013 This opportunity will be limited to investigators with current NIH grant funding for

research and research training being conducted at PEPFAR-funded sites. One year projects that inform the PEPFAR program. Supplement requests cannot exceed $500,000 TOTAL cost Implementation science projects that build in-country research capacity are

encouraged. PEPFAR program areas of interest include:

General Implementation Science for Treatment Programs; Metrics and Diagnostics; Integration of Other Services; Focus on Key Affected Populations (KAP); Behavioral Research; and Training and Health Systems.

Recently Released Program Annoucements

Research on Malignancies in the Context of HIV/AIDS (R01) PA-13-377

http://grants.nih.gov/grants/guide/pa-files/PA-13-377.html

December 7, 2013 is the earliest submission date Research on Malignancies in the Context of HIV/AIDS

(R21) PA-13-378

http://grants.nih.gov/grants/guide/pa-files/PA-13-378.html

December 7, 2013 is the earliest submission date